Updated 06:12 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,842.80 -1.12% CL 88.67 +0.12% BTC 64,299.33 +0.27%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,843 −1.12% BTC $64,299 +0.27% VIX 19.30 +3.21% latest tape · as of 06:12 UTC
The Screen · Consumer Defensive · Beverages - Brewers

C&C Group plc

CCR.L · LSE · GBp · Market cap $39.1B

C&C Group plc manufactures, markets, and distributes beer, cider, wine, spirits, and soft drinks in the United Kingdom, the Republic of Ireland, Great Britain, and internationally.

FAIL · Does not pass the screen
104.80 GBp

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 06:12 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price104.80 GBp at the 13 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 13 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

FAIR-VALUE RANGE

Our fair-value range: 72.44 GBp to 83.31 GBp, base estimate 72.44 GBp (screen dated 2026-11-13).

Current read
Distribution ?
Overvalued · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price104.80 GBp
Fair value72.44
Ethical score30.0/100
Value readOvervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-15Read Distribution104.80+0.0% to today Markup gives way to Distribution first Distribution read since August
2026-10-02Read Markup106.20-1.3% to today Distribution gives way to Markup after an 11% rise in 13 weeks
2026-07-02Read Distribution95.40+9.9% to today First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

C&C Group plc holds its Distribution at $104.80. Consolidating, no directional conviction, held for 6 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 6 days
Price at the screen$104.80
Valuation10,620.00 trailing · 1,109.65 forward price to earnings
Values screenFAIL · score 30.0
Beta0.59
The Workings

Five Screens, Shown in Full

Does not pass. Prohibited business activity: Brewers

TestFigureLimitWhat it meansStatus
Business activity Excluded Core business clean Prohibited business activity: Brewers Fail
Debt load Excluded Below 33% Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash Excluded Below 33% Interest-bearing cash and securities are of assets, above the one-third limit. Fail
Receivables Excluded Below 49% Money owed to the company is of assets, above the 49% limit. Fail
Revenue purity Excluded Below 5% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

C&C does not clear the screen at the business-activity stage. It operates in alcohol, so the financial ratios are not the deciding factor here.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when CCR.L's ethical verdict changes

Today CCR.L does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our 72.44 GBp fair value estimate.

How a fair value is estimated: discounted cash flow (DCF).

72.44Conservative72.44Base case83.31Growth case 104.80Price

Fair value range in GBp, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 44.7% above the base estimate.

The Street's Range
95.69Street low 142.97Street average 297.88Street high 104.80Price

Third-party analyst targets: 6 covering, consensus Buy. The average target sits +36% from the screen price.

Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Projections

Where our models see it going: fair-value estimate 72.44 GBp, with a range of 72.44 GBp to 83.31 GBp, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it gives us pause

At 1,109.7x forward earnings, the price already runs ahead of the business. It trades 45% above our 72.44 GBp fair value, so you would be buying at a premium, not a discount.

The fundamentals · plain-English read
Forward P/E1,109.7xexpensive: the price assumes strong growth ahead
Trailing P/E10,620.0xexpensive: the price assumes strong growth ahead
EPS, trailing0.01
EPS, forward0.10
Revenue growth-7.5%revenue is shrinking
Profit margin0.2%barely profitable
Return on equity0.7%a modest return on shareholder capital
FCF yield5.61%
Dividend yield5.30%
Debt to equity0.77moderate, manageable leverage
Current ratio1.20adequate liquidity, worth monitoring
Beta0.59steadier than the market
52-week range91.50 - 184.59
Market cap$39.1B

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

CCR.L trades on LSE (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-15 Distribution · changed $104.80 -1.5% Entry 10

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-11-08 Markup $106.40 +0.2% Entry 9

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-10-28 Markup $106.20 +0.0% Entry 8

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-10-14 Markup $106.20 +0.0% Entry 7

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-10-02 Markup · changed $106.20 +11.3% Entry 6

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158. Since the last review it its composite score eased.

2026-08-24 Distribution $95.40 +0.0% Entry 5

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-07-24 Distribution $95.40 +0.0% Entry 4

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-07-18 Distribution $95.40 +0.0% Entry 3

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (6 analysts) rates it buy, with a mean price target of $158.

2026-07-03 Distribution $95.40 +0.0% Entry 2

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Distribution $95.40 Entry 1

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $111.40 -13.3% · $867 -13.3%
2 months $123.00 -21.5% · $785 -21.5%
3 months $110.60 -12.7% · $873 -12.7%
6 months $129.00 -25.1% · $749 -25.1%
1 year $168.53 -42.7% $5.36 $605 -39.5%
2 years $157.88 -38.8% $10.51 $678 -32.2%
3 years $136.08 -29.0% $12.14 $799 -20.1%
5 years $237.72 -59.4% $15.42 $471 -52.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CCR.L does next, these words stay.

C&C Group plc · CCR.L · Distribution · $104.80
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.